Tuesday, April 27, 2010

Migraine Drug Telcagepant to Undergo Another Clinical Safety Study


New to Somebody Heal Me? Subscribe to the Somebody Heal Me feed:
Subscribe in a reader or subscribe by e-mail. Follow me on Twitter @somebodyhealme.

When results from initial clinical trials indicated that patients taking migraine medication telcagepant had elevated liver enzymes, there was much speculation about how the drug's manufacturer Merck would proceed. When Merck announced the disappointing results in September they said they would confer with the FDA about how to move forward. They recently announced they will put telcagepant through another clinical safety study.

Migraine Patients to Wait for Triptan Alternative

Telcagepant is part of a category of new migraine medications called CGRP receptor antagonists. These medications exploit the discovery that many patients experience a rise in CGRP levels during a migraine attack. These drugs are thought to be safe for people with cardiovascular problems, who cannot safely use triptans such as Imitrex or Relpax for migraine treatment. We'll have to wait and see if the safety issues continue to be a concern.

Related:
News: Telcagepant to be Abandoned by Merck?
Telcagepant & The Future of Migraine Prevention
Possible Genetic Explanation for Migraine
Migraine News Roundup 34



Subscribe to the Somebody Heal Me feed: Subscribe in a reader or subscribe by e-mail.

Photo Sharing and Video Hosting at Photobucket Content by Diana E. Lee.
DISCLAIMER: Nothing on this site constitutes medical or legal advice. I am a patient who is engaged and educated and enjoys sharing my experiences and news about migraines, pain and depression. Please consult your own health care providers for advice on your unique situation.